World's Best Scientists 2026 revealed!
Edward C. Keystone

Edward C. Keystone

D-Index & Metrics

Medicine

D-Index
99
Citations
53894
World Ranking
8425
National Ranking
326

Edward C. Keystone publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Edward C. Keystone sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 575 publications — 69th percentile

69% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Edward C. Keystone D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Edward C. Keystone sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 99 D-Index — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Edward C. Keystone is affiliated with the University of Toronto in Canada and specializes in medical research. Their work focuses prominently on rheumatology, with extensive contributions in related fields such as hematology, genetics, immunology, and pathology and forensic medicine.

Keystone's research spans a variety of topics, including:

  • Rheumatoid Arthritis Research and Therapies
  • Biosimilars and Bioanalytical Methods
  • Autoimmune and Inflammatory Disorders Research
  • Chronic Lymphocytic Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Pharmaceutical Studies and Practices
  • Systemic Lupus Erythematosus Research

They have published extensively in several scientific journals. The most frequent publication venues include:

  • Annals of the Rheumatic Diseases
  • Lara D. Veeken
  • ACR Open Rheumatology
  • RMD Open
  • Arthritis & Rheumatology

Notable recent papers authored or co-authored by Keystone include:

  • Multi-ancestry genome-wide association analyses identify novel genetic mechanisms in rheumatoid arthritis, 2022, Nature Genetics
  • Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib, 2020, RMD Open
  • Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study, 2021, Arthritis Research & Therapy
  • Primary and secondary non-response: in need of operational definitions in observational studies, 2021, Annals of the Rheumatic Diseases
  • Improvements in Fatigue Lag Behind Disease Remission in Early Rheumatoid Arthritis: Results From the Canadian Early Arthritis Cohort, 2020, Arthritis & Rheumatology

They collaborate frequently with other researchers in their field. Primary co-authors include:

  • Janet Pope
  • Louis Bessette
  • Glen Hazlewood
  • Susan J. Bartlett
  • Gilles Boire

Best Publications

  • Treating rheumatoid arthritis to target: recommendations of an international task force

    Josef S. Smolen;Daniel Aletaha;Johannes W J W Bijlsma;Ferdinand C Breedveld

  • Genetics of rheumatoid arthritis contributes to biology and drug discovery

    Yukinori Okada;Yukinori Okada;Di Wu;Di Wu;Di Wu;Gosia Trynka;Gosia Trynka;Towfique Raj;Towfique Raj

  • Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy : Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

    Stanley B Cohen;Paul Emery;Maria W Greenwald;Maxime Dougados

  • A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis

    Joan M. Bathon;Richard W. Martin;Roy M. Fleischmann;John R. Tesser

  • Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

    Michael E. Weinblatt;Edward C. Keystone;Daniel E. Furst;Larry W. Moreland

  • Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial

    Larry W. Moreland;Michael H. Schiff;Scott W. Baumgartner;Elizabeth A. Tindall

  • American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials

    David T. Felson;David T. Felson;Josef S. Smolen;George Wells;Bi Zhang

  • Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trial

    Edward C. Keystone;Arthur F. Kavanaugh;John T. Sharp;Hyman Tannenbaum

  • Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

    E William St Clair;Désirée M F M van der Heijde;Josef S Smolen;Ravinder N Maini

  • Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010

    D. E. Furst;E. C. Keystone;J. Braun;F. C. Breedveld

  • Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management

    Michael A Gardam;Edward C Keystone;Richard Menzies;Steven Manners

  • Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes.

    Mark C. Genovese;Joan M. Bathon;Richard W. Martin;Roy M. Fleischmann

  • IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

    P Emery;E Keystone;H P Tony;A Cantagrel

  • Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).

    Christian E. Antoni;Arthur Kavanaugh;Bruce Kirkham;Zuhre Tutuncu

  • Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

    Edward Keystone;Désireé Van Der Heijde;David Mason;Robert Landewé

  • Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

    Edward C. Keystone;Mark C. Genovese;Lars Klareskog;Elizabeth C. Hsia

  • Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations.

    D. Aletaha;R.B. Landewe;T. Karonitsch;J. Bathon

  • Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study

    Désirée van der Heijde;Yoshiya Tanaka;Roy Fleischmann;Edward Keystone

  • The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial.

    E. William St.Clair;Carrie L. Wagner;Adedigbo A. Fasanmade;Benjamin Wang

  • Predictors of joint damage in patients with early rheumatoid arthritis treated with high‐dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial

    Josef S. Smolen;Désirée M. F. M. Van Der Heijde;E. William St.Clair;Paul Emery

Frequent Co-Authors

Janet E. Pope
Janet E. Pope University of Western Ontario
Paul Emery
Paul Emery University of Leeds
Mark C. Genovese
Mark C. Genovese Stanford University
Désirée van der Heijde
Désirée van der Heijde Leiden University Medical Center
Daniel E. Furst
Daniel E. Furst University of California, Los Angeles
Michael E. Weinblatt
Michael E. Weinblatt Brigham and Women's Hospital
Bernard Combe
Bernard Combe University of Montpellier
Roy Fleischmann
Roy Fleischmann The University of Texas Southwestern Medical Center
Robert Landewé
Robert Landewé University of Amsterdam
Josef S. Smolen
Josef S. Smolen Medical University of Vienna

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always follow a single path. Today, online degrees offer flexible options for those interested in healthcare careers, whether you aim for clinical roles or vital support positions. One fast-track option for nurses is the 1 year dnp program online, which can significantly accelerate your journey to a leadership role in nursing practice.

For those more interested in pharmacy, consider advancing your credentials through an online pharmd program. This pathway prepares you for a wider range of professional opportunities in pharmaceutical care and research.

Students who want to work in healthcare management or information systems can choose rhit programs online. These programs are ideal for understanding health records, privacy laws, and electronic data systems.

Lastly, medical billing and coding remains a popular entry point into healthcare. Understanding the medical coding certification cost helps you budget for quick training that can lead to in-demand remote job opportunities.

Best Scientists Citing Edward C. Keystone

Trending Scientists

Recently Published Articles